• Badri M, Wilson D & Wood R (2002) Effect of highly active antiretroviral therapy on incidence on tuberculosis in South Africa: a cohort study. Lancet359, 20592064.
  • Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE & Delfraissy JF (2007) Treatment strategies for HIV infected patients with tuberculosis: ongoing and planned clinical trials. Journal of Infectious Diseases196, S46S51.
  • Chattopadhya D, Baveja UK, Bose M & Kumar A (2002) Disease progression markers during asymptomatic phase of HIV-1 infected children with unimpaired CD4 +  cell values: evaluation of repeat CD4 +  cell evaluation vs. other immunological parameters. Journal of Tropical Pediatrics48, 340347.
  • Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J & De Cock KM (2000) Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease4, 705712.
  • Corbett EL, Watt CJ, Walker N et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine163, 10091021.
  • Couzigou C, Semaille C, Le Strat Y et al. (2007) Differential improvement in survival among patients with AIDS after the introduction of HAART. AIDS Care19, 523531.
  • Cowley SC & Elkins KL (2003) CD4 +  T cells mediate IFN-g-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. Journal of Immunology171, 46894699.
  • Daley CL, Small PM, Schecter GF et al. (1992) An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus. An analysis using restriction fragment-length polymorphism. New England Journal of Medicine326, 231235.
  • Dheda K, Lampe FC, Johnson MA & Lipman MC (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Journal of Infectious Diseases190, 16701676.
  • García de Olalla P, Martínez-González MA, Caylà JA et al. (2002) Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients. International Journal of Tuberculosis and Lung Disease6, 10511057.
  • Havlir D, Ive P, Kendall M et al. (2011) International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE study [Abstract 38]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts.
  • Henderson R, Diggle P & Dobson A (2000) Joint modeling of longitudinal measurements and event time data. Biostatistics4, 465480.
  • Hoover DR, Rinaldo C, He Y, Phair J, Fahey ZJ & Graham MH (1995) Long term survival without clinical AIDS after CD4 +  cell counts fell below 200 x 106/L. AIDS9, 145152.
  • Joint United Nations Programme on HIV/AIDS/World Health Organization (2003) AIDS Epidemic Update: December 2003. UNAIDS/WHO, Geneva, Switzerland. Available at: (accessed March 2004).
  • Karim SS, Naidoo K, Grobler A et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. The New England Journal of Medicine362, 697706.
  • Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A & Sungkanuparph S (2006) Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome43, 4246.
  • McIlleron H, Meintjes G, Burman WJ & Maartens G (2007) Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. Journal of Infectious Diseases196, S63S75.
  • Mukadi YD, Maher D & Harries A (2000) Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS15, 143152.
  • Nahid P, Gonzalez LC, Rudoy I et al. (2007) Treatment outcomes of patients with HIV and Tuberculosis. American Journal of Respiratory and Critical Care Medicine175, 11991206.
  • Peterson J, Church J, Gowperts E & Parkman R (1989) Lymphocyte phenotype does not predict immune function in paediatric patients infected with human immunodeficiency virus type-1. Journal of Pediatrics115, 944950.
  • Santoro-Lopes G, Felix AM, Harrison LH et al. (2002) Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clinical Infectious Diseases34, 543546.
  • TB India (2007), RNTCP Status Report. Central TB Division, Ministry of Health and Family Welfare, New Delhi. (accessed 20 December 2010).
  • Toossi Z (2003) Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. Journal of Infectious Diseases188, 11461155.
  • Tsiatis AA & Davidian M (2004) Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica14, 793818.
  • Wolday D, Hailu B, Girma M et al. (2003) Low CD4 + T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV positive Ethiopians. International Journal of Tuberculosis and Lung Disease7, 110116.
  • World Health Organisation (2003) Revised WHO guidelines for scaling up antiretroviral therapy in resource-limited settings. revision.